

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7186412

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
AIMMUNE THERAPEUTICS, INC.	12/02/2021

RECEIVING PARTY DATA

Name:	SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Street Address:	AVENUE NESTLÉ 55
City:	VEVEY
State/Country:	SWITZERLAND
Postal Code:	1800

PROPERTY NUMBERS Total: 17

Property Type	Number
Patent Number:	9492535
Patent Number:	10086068
Patent Number:	10653773
Patent Number:	10512686
Application Number:	16842675
Patent Number:	9198869
Patent Number:	10449118
Patent Number:	10918676
Application Number:	15870477
Application Number:	16178502
Application Number:	16523875
Patent Number:	D866320
Patent Number:	D866321
Patent Number:	D866322
Application Number:	16542198
Application Number:	16721805
Application Number:	16953183

CORRESPONDENCE DATA

Fax Number: (650)494-0792

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

PATENT

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (650) 813-6496
Email: cpicazomejia@mofo.com
Correspondent Name: STEPHEN D. FRAUSTO
Address Line 1: MORRISON & FOERSTER LLP
Address Line 2: 755 PAGE MILL ROAD
Address Line 4: PALO ALTO, CALIFORNIA 94304-1018

ATTORNEY DOCKET NUMBER:	77627-VARIOUS
NAME OF SUBMITTER:	STEPHEN D. FRAUSTO
SIGNATURE:	/Stephen Frausto/
DATE SIGNED:	02/21/2022

Total Attachments: 10

source=Aimmune_to_SPN_77627-VARIOUS#page1.tif
source=Aimmune_to_SPN_77627-VARIOUS#page2.tif
source=Aimmune_to_SPN_77627-VARIOUS#page3.tif
source=Aimmune_to_SPN_77627-VARIOUS#page4.tif
source=Aimmune_to_SPN_77627-VARIOUS#page5.tif
source=Aimmune_to_SPN_77627-VARIOUS#page6.tif
source=Aimmune_to_SPN_77627-VARIOUS#page7.tif
source=Aimmune_to_SPN_77627-VARIOUS#page8.tif
source=Aimmune_to_SPN_77627-VARIOUS#page9.tif
source=Aimmune_to_SPN_77627-VARIOUS#page10.tif

ENTITY TO ENTITY ASSIGNMENT

This Assignment is by:

Assignor: Aimimmune Therapeutics, Inc.
Address: 8000 Marina Boulevard, Suite 300
Brisbane, California 94005
A juristic entity duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignor"), which is the sole and exclusive owner, by assignment, of the patents and patent applications identified in **Schedule A**, appended hereto.

This Assignment is to:

Assignee: Société des Produits Nestlé S.A.
Address: Avenue Nestlé 55
1800 Vevey, Switzerland
A juristic entity duly organized under and pursuant to the laws of: Switzerland

(referred to in this Assignment as "Assignee"), which desires to acquire the entire right, title and interest in, to and under said patents and patent applications, and the inventions covered thereby, in accordance with the Intangible Property Transfer and Assignment and Assumption Agreement (the "IPTAA Agreement") made between the Assignor and Assignee, effective on October 20, 2020.

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement, including the IPTAA Agreement, with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement, including the IPTAA Agreement, with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement

1. Assignor hereby sells, assigns, transfers and sets over, to Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to the above-mentioned inventions, application for letters patent, and any and all non-provisionals, divisions, continuations, and continuations-in part claiming priority thereto or the benefit thereof, substitutions of said applications, and any and all letters patent or patents in the United States of America and all foreign countries or jurisdictions which may be granted therefor and thereon, including, without limitation, any modifications to such letters patent or patents such as through reissue, re-examination or other post-grant proceeding, and any and all extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover damages for past, present and future infringement, and any and all rights to claim priority to said application and any and all applications claiming priority thereto or based on said inventions), for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignor, had this sale and assignment not been made.
2. Assignor hereby authorizes and requests the Commissioner for Patents in the United States to issue the above mentioned letters patents of the United States and any reissue, reexamination, review, or extension thereof to and in the name of Assignee as the assignee of said inventions and the letters patent to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.
3. Assignor hereby grants Assignee's attorneys, all of Morrison & Foerster LLP (or as needed attorneys of the applicable country appointed and authorized by Morrison & Foerster LLP), the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States

sf-4579191

Patent and Trademark office or any foreign patent issuing authority for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known.

4. This assignment may be executed in one or more counterparts, with the same effect as if each signature were on the same document. Each counterpart so executed shall be deemed to be an original, and all such counterparts shall be construed together and shall constitute one agreement.

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

ASSIGNOR:

Date: 12/2/21

Signature: [Signature]
Name: JAMES PEPIN
Title: SVP & GENERAL COUNSEL
Company: Aimmune Therapeutics, Inc.

ASSIGNEE:

Date: 6/12/2021

Signature: [Signature]
Name: Anna Maria Rodriguez
Title: General Counsel, Research & Development
Company: Société des Produits Nestlé S.A.

SCHEDULE A

All dates in month/date/year format

No.	Country	Title	Application No. App. Date	Patent / Pub. No.
1.	United States of America	PEANUT FORMULATIONS AND USES THEREOF	14/207,127 3/12/2014	9,492,535
2.	United States of America	PEANUT FORMULATIONS AND USES THEREOF	15/276,440 9/26/2016	10,086,068
3.	United States of America	PEANUT FORMULATIONS AND USES THEREOF	16/111,102 8/23/2018	10,653,773
4.	United States of America	PEANUT FORMULATIONS AND USES THEREOF	16/289,370 2/28/2019	10,512,686
5.	United States of America	PEANUT FORMULATIONS AND USES THEREOF	16/842,675 4/7/2020	US-2021-0052722-A1
6.	United States of America	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14/207,165 3/12/2014	9,198,869
7.	United States of America	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	15/792,716 10/24/2017	10,449,118
8.	United States of America	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	16/453,871 6/26/2019	11,141,352
9.	United States of America	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	17/412,170 8/25/2021	
10.	Australia	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	2014240404 3/12/2014	2014240404
11.	Brazil	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	BR1120150217567 3/12/2014	BR1120150217567
12.	Canada	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	2,903,229 3/12/2014	2,903,229
13.	China	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	201480013792.4 3/12/2014	ZL 201480013792.4
14.	European Patent Office	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
15.	India	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	2523/MUMNP/2015 8/31/2015	IN201502523P3
16.	Japan	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	2016-501522 3/12/2014	6752140
17.	Mexico	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	MX/a/2015/010315 3/12/2014	MX/a/2015/010315A
18.	Australia	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	2016231523 9/21/2016	2016231523
19.	Hong Kong	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	16105808.3 5/20/2016	HK1217660B

sf-4579191

No.	Country	Title	Application No. App. Date	Patent / Pub. No.
20.	Japan	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	2019-34083 3/12/2014	6891205
21.	China	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	201811093370.9 3/12/2014	CN 109125283 A
22.	European Patent Office	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	18213124.3 3/12/2014	3482771
23.	Hong Kong	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	19126156.9 7/2/2019	HK40003142A
24.	Hong Kong	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	19131896.3 11/6/2019	HK40008413A
25.	Australia	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	2020202685 4/22/2020	2020202685
26.	Austria	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
27.	Belgium	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
28.	Switzerland	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
29.	Germany	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	60 2014 068 617.6
30.	Denmark	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
31.	Spain	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
32.	Finland	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
33.	France	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
34.	United Kingdom	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
35.	Greece	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
36.	Hungary	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
37.	Ireland	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
38.	Italy	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	502020000102109

sf-4579191

No.	Country	Title	Application No. App. Date	Patent / Pub. No.
39.	Luxembourg	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
40.	Netherlands	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
41.	Norway	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
42.	Poland	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
43.	Portugal	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
44.	Sweden	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
45.	Slovenia	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2968529
46.	Turkey	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	14776121.7 3/12/2014	2020/16185
47.	Japan	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	2021-25462 3/12/2014	JP 2021-073321 A
48.	European Patent Office	MANUFACTURE OF PEANUT FORMULATIONS FOR ORAL DESENSITIZATION	EP21199373.8 9/28/2021	
49.	United States of America	EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF	14/835,336 8/25/2015	US-2016-0051593-A1
50.	United States of America	EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF	16/396,493 4/26/2019	10,918,676
51.	Australia	EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF	2015306683 8/25/2015	2015306683
52.	Canada	EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF	2,955,252 8/25/2015	2,955,252
53.	China	EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF	201580040032.7 8/25/2015	CN 106535931 A
54.	European Patent Office	EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF	15837009.8 8/25/2015	3185900
55.	Japan	EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF	2017-504432 8/25/2015	6910946
56.	Republic of Korea	EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF	10-2017-7004749 8/25/2015	1020170044111
57.	New Zealand	EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF	729082 8/25/2015	729082A1

sf-4579191

No.	Country	Title	Application No. App. Date	Patent / Pub. No.
58.	Japan	EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF	2019-223035 12/10/2019	JP 2020-059734 A
59.	New Zealand	EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF	767226 8/19/2020	
60.	Japan	EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF	2021-119489 7/20/2021	
61.	United States of America	METHODS OF MANUFACTURE OF NUT FLOURS AND FORMULATIONS FOR ORAL IMMUNOTHERAPY	15/870,477 1/12/2018	US-2018-0200361-A1
62.	Australia	METHODS OF MANUFACTURE OF NUT FLOURS AND FORMULATIONS FOR ORAL IMMUNOTHERAPY	2018207167 1/12/2018	2018207167
63.	Canada	METHODS OF MANUFACTURE OF NUT FLOURS AND FORMULATIONS FOR ORAL IMMUNOTHERAPY	3,050,093 1/12/2018	3,050,093
64.	China	METHODS OF MANUFACTURE OF NUT FLOURS AND FORMULATIONS FOR ORAL IMMUNOTHERAPY	2018800166910 1/12/2018	CN 110381749 A
65.	European Patent Office	METHODS OF MANUFACTURE OF NUT FLOURS AND FORMULATIONS FOR ORAL IMMUNOTHERAPY	18739367.3 1/12/2018	3568027
66.	Israel	METHODS OF MANUFACTURE OF NUT FLOURS AND FORMULATIONS FOR ORAL IMMUNOTHERAPY	267882 1/12/2018	267882A
67.	India	METHODS OF MANUFACTURE OF NUT FLOURS AND FORMULATIONS FOR ORAL IMMUNOTHERAPY	201917027657 1/12/2018	IN201917027657A
68.	Japan	METHODS OF MANUFACTURE OF NUT FLOURS AND FORMULATIONS FOR ORAL IMMUNOTHERAPY	2019-538225 1/12/2018	JP 2020-514306 A
69.	Mexico	METHODS OF MANUFACTURE OF NUT FLOURS AND FORMULATIONS FOR ORAL IMMUNOTHERAPY	MX/a/2019/008419 7/12/2019	MX/a/2019/008419
70.	Singapore	METHODS OF MANUFACTURE OF NUT FLOURS AND FORMULATIONS FOR ORAL IMMUNOTHERAPY	11201906301U 7/4/2019	11201906301U
71.	Singapore	METHODS OF MANUFACTURE OF NUT FLOURS AND FORMULATIONS FOR ORAL IMMUNOTHERAPY	10201913846X 12/30/2019	10201913846X
72.	Hong Kong	METHODS OF MANUFACTURE OF NUT FLOURS AND FORMULATIONS FOR ORAL IMMUNOTHERAPY	62020006429.8 4/24/2020	HK40016989A
73.	Hong Kong	METHODS OF MANUFACTURE OF NUT FLOURS AND FORMULATIONS FOR ORAL IMMUNOTHERAPY	62020007496.6 5/14/2020	HK40017880A
74.	United States of America	METHODS OF ORAL IMMUNOTHERAPY	16/178,502 11/1/2018	US-2019-0167785-A1
75.	Australia	METHODS OF ORAL IMMUNOTHERAPY	2018358125 11/1/2018	2018358125
76.	Canada	METHODS OF ORAL IMMUNOTHERAPY	3,080,601 11/1/2018	3,080,601
77.	China	METHODS OF ORAL IMMUNOTHERAPY	201880071608X 11/1/2018	CN 111344010 A
78.	European Patent Office	METHODS OF ORAL IMMUNOTHERAPY	18871949.6 11/1/2018	3703743

sf-4579191

No.	Country	Title	Application No. App. Date	Patent / Pub. No.
79.	Japan	METHODS OF ORAL IMMUNOTHERAPY	2020-524388 11/1/2018	JP 2021-501763 A
80.	Republic of Korea	METHODS OF ORAL IMMUNOTHERAPY	10-2020-7015239 11/1/2018	1020200083526
81.	Mexico	METHODS OF ORAL IMMUNOTHERAPY	MX/a/2020/004683 11/1/2018	MX/a/2020/004683
82.	New Zealand	METHODS OF ORAL IMMUNOTHERAPY	763862 11/1/2018	763862
83.	Hong Kong	METHODS OF ORAL IMMUNOTHERAPY	62021026311.2 2/25/2021	40036960
84.	United States of America	ORAL IMMUNOTHERAPY UNIT DOSE DISPENSING SYSTEMS AND METHODS	16/523,875 7/26/2019	US-2020-0030187-A1
85.	Australia	ORAL IMMUNOTHERAPY UNIT DOSE DISPENSING SYSTEMS AND METHODS	2019310602 7/26/2019	2019310602
86.	Canada	ORAL IMMUNOTHERAPY UNIT DOSE DISPENSING SYSTEMS AND METHODS	3,107,667 7/26/2019	3,107,667
87.	China	ORAL IMMUNOTHERAPY UNIT DOSE DISPENSING SYSTEMS AND METHODS	2019800500713 7/26/2019	CN 112638413 A
88.	European Patent Office	ORAL IMMUNOTHERAPY UNIT DOSE DISPENSING SYSTEMS AND METHODS	19839815.8 7/26/2019	3829632
89.	Japan	ORAL IMMUNOTHERAPY UNIT DOSE DISPENSING SYSTEMS AND METHODS	2021-504260 1/25/2021	2021-504260
90.	United States of America	BOX OF BOXES FOR DISPENSING MEDICINE	29/658,124 7/27/2018	D866320
91.	Argentina	BOX OF BOXES FOR DISPENSING MEDICINE	94568 1/25/2019	94568
92.	Australia	BOX OF BOXES FOR DISPENSING MEDICINE	201910404 1/25/2019	201910404
93.	Brazil	BOX OF BOXES FOR DISPENSING MEDICINE	BR 30 2019 0003392 1/28/2019	BR 30 2019 0003392
94.	China	BOX OF BOXES FOR DISPENSING MEDICINE	2019300429171 1/25/2019	CN305329290S
95.	India	BOX OF BOXES FOR DISPENSING MEDICINE	314242-001 1/25/2019	86797
96.	Israel	BOX OF BOXES FOR DISPENSING MEDICINE	63239 1/27/2019	63239
97.	Japan	BOX OF BOXES FOR DISPENSING MEDICINE	2019-001387 1/25/2019	1636521
98.	Mexico	BOX OF BOXES FOR DISPENSING MEDICINE	MX/I/2019/000260 1/25/2019	60570
99.	New Zealand	BOX OF BOXES FOR DISPENSING MEDICINE	425637 1/25/2019	425637
100.	Russian Federation	BOX OF BOXES FOR DISPENSING MEDICINE	2019500160 1/21/2019	116361
101.	United Kingdom	BOX OF BOXES FOR DISPENSING MEDICINE	6053145 1/25/2019	6053145
102.	Hague Convention (Int'l)	BOX OF BOXES FOR DISPENSING MEDICINE	35/001,633 1/24/2019	DM/206564
103.	United Arab Emirates	BOX OF BOXES FOR DISPENSING MEDICINE	D6000039/2019 1/27/2019	5926
104.	Israel	BOX OF BOXES FOR DISPENSING MEDICINE	64585 1/27/2019	64585
105.	Canada	BOX OF BOXES FOR DISPENSING MEDICINE	35/001,633 1/24/2019	DM/206564
106.	Switzerland	BOX OF BOXES FOR DISPENSING MEDICINE	35/001,633 1/24/2019	DM/206564

sf-4579191

No.	Country	Title	Application No. App. Date	Patent / Pub. No.
107.	European Union	BOX OF BOXES FOR DISPENSING MEDICINE	35/001,633 1/24/2019	DM/206564
108.	Republic of Korea	BOX OF BOXES FOR DISPENSING MEDICINE	35/001,633 1/24/2019	DM/206564
109.	Norway	BOX OF BOXES FOR DISPENSING MEDICINE	35/001,633 1/24/2019	DM/206564
110.	Singapore	BOX OF BOXES FOR DISPENSING MEDICINE	35/001,633 1/24/2019	DM/206564
111.	Turkey	BOX OF BOXES FOR DISPENSING MEDICINE	35/001,633 1/24/2019	DM/206564
112.	Mexico	BOX OF BOXES FOR DISPENSING MEDICINE	MX/ff2020/002880 11/20/2020	
113.	Patent Cooperation Treaty	METHODS OF TREATING PEANUT ALLERGY BY ORAL IMMUNOTHERAPY WITH LOW-DOSE MAINTENANCE	PCT/US2020/034311 5/22/2020	WO 2020/237181
114.	United States of America	BOX OF BOXES FOR DISPENSING MEDICINE	29/658,129 7/27/2018	D866321
115.	Argentina	BOX OF BOXES FOR DISPENSING MEDICINE	94569 1/25/2019	94569
116.	Australia	BOX OF BOXES FOR DISPENSING MEDICINE	201910406 1/25/2019	201910406
117.	India	BOX OF BOXES FOR DISPENSING MEDICINE	314241-001 1/25/2019	314241-001
118.	Japan	BOX OF BOXES FOR DISPENSING MEDICINE	2019-001386 1/25/2019	1636520
119.	New Zealand	BOX OF BOXES FOR DISPENSING MEDICINE	425638 1/25/2019	425638
120.	Russian Federation	BOX OF BOXES FOR DISPENSING MEDICINE	2019500159 1/21/2019	116772
121.	United Arab Emirates	BOX OF BOXES FOR DISPENSING MEDICINE	D6000040/2019 1/27/2019	5927
122.	United Kingdom	BOX OF BOXES FOR DISPENSING MEDICINE	6053146 1/25/2019	6053146
123.	United States of America	MEDICINE FOLIO	29/658,130 7/27/2018	D866322
124.	Argentina	MEDICINE FOLIO	94570 1/25/2019	94570
125.	Australia	MEDICINE FOLIO	201910402 1/25/2019	201910402
126.	Brazil	MEDICINE FOLIO	BR 30 2019 0003422 1/28/2019	BR 30 2019 0003422
127.	China	MEDICINE FOLIO	201930042665.2 1/25/2019	CN305346255S
128.	India	MEDICINE FOLIO	314243-001 1/25/2019	314243-001
129.	Israel	MEDICINE FOLIO	63241 1/27/2019	63241
130.	Japan	MEDICINE FOLIO	2019-001388 1/25/2019	1637805
131.	Mexico	MEDICINE FOLIO	MX/ff2019/000259 1/25/2019	59197
132.	New Zealand	MEDICINE FOLIO	425636 1/25/2019	425636
133.	Russian Federation	BLISTER PACKAGE	2019500211 1/25/2019	116770
134.	United Kingdom	MEDICINE FOLIO	6053147 1/25/2019	6053147

sf-4579191

No.	Country	Title	Application No. App. Date	Patent / Pub. No.
135.	Hague Convention (Int'l)	MEDICINE FOLIO	35/001,634 1/24/2019	DM/207638
136.	United Arab Emirates	MEDICINE FOLIO	D6000041/2019 1/27/2019	5928
137.	Israel	MEDICINE FOLIO	64394 1/26/2019	64394
138.	Canada	MEDICINE FOLIO	35/001,634 1/24/2019	DM/207638
139.	Switzerland	MEDICINE FOLIO	35/001,634 1/24/2019	DM/207638
140.	European Union	MEDICINE FOLIO	35/001,634 1/24/2019	DM/207638
141.	Republic of Korea	MEDICINE FOLIO	35/001,634 1/24/2019	DM/207638
142.	Norway	MEDICINE FOLIO	35/001,634 1/24/2019	DM/207638
143.	Singapore	MEDICINE FOLIO	35/001,634 1/24/2019	DM/207638
144.	Turkey	MEDICINE FOLIO	35/001,634 1/24/2019	DM/207638
145.	United States of America	PEANUT ORAL IMMUNOTHERAPY WITH MAINTENANCE DOSE	16/542,198 8/15/2019	US-2020-0054738-A1
146.	European Patent Office	PEANUT ORAL IMMUNOTHERAPY WITH MAINTENANCE DOSE	19849215.9 8/15/2019	3836801
147.	United States of America	FORMULATIONS FOR EGG ORAL IMMUNOTHERAPY, METHODS OF MANUFACTURE, AND TREATMENTS FOR EGG ALLERGY	17/414,288 6/15/2021	
148.	Australia	FORMULATIONS FOR EGG ORAL IMMUNOTHERAPY, METHODS OF MANUFACTURE, AND TREATMENTS FOR EGG ALLERGY	2019401576 12/17/2019	
149.	Canada	FORMULATIONS FOR EGG ORAL IMMUNOTHERAPY, METHODS OF MANUFACTURE, AND TREATMENTS FOR EGG ALLERGY	3122854 12/17/2019	
150.	China	FORMULATIONS FOR EGG ORAL IMMUNOTHERAPY, METHODS OF MANUFACTURE, AND TREATMENTS FOR EGG ALLERGY	201980091171.0 12/17/2019	
151.	European Patent Office	FORMULATIONS FOR EGG ORAL IMMUNOTHERAPY, METHODS OF MANUFACTURE, AND TREATMENTS FOR EGG ALLERGY	19898986.5 12/17/2019	
152.	Japan	FORMULATIONS FOR EGG ORAL IMMUNOTHERAPY, METHODS OF MANUFACTURE, AND TREATMENTS FOR EGG ALLERGY	2021-534720 12/17/2019	
153.	United States of America	PEANUT ORAL IMMUNOTHERAPY DOSING SCHEDULE FOR MISSED DOSES	16/721,805 12/19/2019	US-2020-0230206-A1
154.	Australia	PEANUT ORAL IMMUNOTHERAPY DOSING SCHEDULE FOR MISSED DOSES	2019401214 12/19/2019	
155.	Canada	PEANUT ORAL IMMUNOTHERAPY DOSING SCHEDULE FOR MISSED DOSES	3123605 12/19/2019	

sf-4579191

No.	Country	Title	Application No. App. Date	Patent / Pub. No.
156.	China	PEANUT ORAL IMMUNOTHERAPY DOSING SCHEDULE FOR MISSED DOSES	201980084430.7 12/19/2019	
157.	European Patent Office	PEANUT ORAL IMMUNOTHERAPY DOSING SCHEDULE FOR MISSED DOSES	19898993.1 12/19/2019	
158.	Japan	PEANUT ORAL IMMUNOTHERAPY DOSING SCHEDULE FOR MISSED DOSES	2021-535843 12/19/2019	
159.	Patent Cooperation Treaty	SYSTEMIC ALLERGIC RESPONSE RISK ASSESSMENT IN PEANUT ORAL IMMUNOTHERAPY	PCT/US2020/023903 3/20/2020	WO 2020/198024
160.	United States of America	METHODS FOR IMPROVING THE QUALITY OF LIFE OF A PATIENT WITH A PEANUT ALLERGY	16/870,696 5/8/2020	US-2020-0368304-A1
161.	Patent Cooperation Treaty	METHODS FOR IMPROVING THE QUALITY OF LIFE OF A PATIENT WITH A PEANUT ALLERGY	PCT/US2020/032179 5/8/2020	WO 2020/231843
162.	United States of America	DETERMINING MEDICAL STAFFING FOR ORAL IMMUNOTHERAPY	17/364,518 6/30/2021	
163.	United States of America	METHODS AND SYSTEMS FOR MANAGING DISTRIBUTION AND TREATMENT OF A FOOD ALLERGY ORAL IMMUNOTHERAPY DRUG	16/953,183 11/19/2020	US-2021-0151155-A1
164.	Patent Cooperation Treaty	METHODS AND SYSTEMS FOR MANAGING DISTRIBUTION AND TREATMENT OF A FOOD ALLERGY ORAL IMMUNOTHERAPY DRUG	PCT/US2020/061362 11/19/2020	WO 2021/102186

sf-4579191